← All trials
NCT01640782
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2005
- Primary completion
- Jan 1, 2013
- Completion date
- Jan 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 1100
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Mario Negri InstituteLead sponsor
- University of MilanOverall official - principal investigator
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteCollaborator
- Gruppo Oncologico Italiano di Ricerca ClinicaCollaborator
- Gruppo Oncologico del Nord-OvestCollaborator
- Italian Trial in Medical OncologyCollaborator
- Southern Italy Cooperative Oncology GroupCollaborator
- OncotechCollaborator
- Istituto Nazionale per lo Studio e la Cura dei TumoriCollaborator
- AventisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.